Results 161 to 170 of about 3,541,930 (355)

Term Structure Model for Sri Lankan Bond Market

, 2022
Lorraine Dehoedt, J.K. Wijerathna
openalex   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

P18 High satisfaction scores but high rates of unmet need- what is missing in breast cancer survivorship care?

Breast, 2020
D. Vuksanovic, J. Sanmugarajah, D. Lunn, R. Sawhney, K. Eu, R. Liang   +5 more
doaj   +1 more source

In Vivo Therapeutic Potential of Biologically Synthesized Nanoparticles From Pine Needle Leaf Extract in Streptozotocin-Induced Diabetic Rats. [PDF]

Biomed Res Int
Darwich NA, Abouzeinab NS, El-Sayed AF, El Hajj R, Khalil MI.   +4 more
europepmc   +1 more source

Bond strength of orthodontic direct-bonding cement-bracket systems as studied in vitro

, 1982
V.A.James Buzzitta, Steven E. Hallgren, John M. Powers   +2 more
openalex   +2 more sources

The Effect of Different Post Space Surface Treatments on Push-out Bond Strength of Fiber Posts Adhesively Bonded to Root Canal Dentin [PDF]

, 2019
Mostafa Aboushahba
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Microshear Bond Strength of Composite Resin to Mineral Trioxide Aggregate and Potassium Nitrate-Modified Polycarboxylate Cement at Two Time Points Using Different Adhesive Approaches: An In Vitro Study. [PDF]

Clin Exp Dent Res
Adl A, Jowkar Z, Zerafat M, Sobhnamayan F.   +3 more
europepmc   +1 more source

The aeroplane is talking to you: What you should do to listen to it [PDF]

, 2011
Bond, S.J.
core  

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source